{"name": "Ceptaris Therapeutics", "permalink": "ceptaris-therapeutics", "crunchbase_url": "http://www.crunchbase.com/company/ceptaris-therapeutics", "homepage_url": "http://www.ceptaris.com/", "blog_url": "", "blog_feed_url": "", "twitter_username": "", "category_code": "biotech", "number_of_employees": null, "founded_year": null, "founded_month": null, "founded_day": null, "deadpooled_year": null, "deadpooled_month": null, "deadpooled_day": null, "deadpooled_url": null, "tag_list": "", "alias_list": "", "email_address": "", "phone_number": "610-975-9290 ", "description": "", "created_at": "Wed Feb 22 04:04:36 UTC 2012", "updated_at": "Wed Feb 22 04:04:36 UTC 2012", "overview": "\u003Cp\u003ECeptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris\u0026#8217; investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.\u003C/p\u003E", "image":  {"available_sizes":    [[[150,       42],      "assets/images/resized/0017/5338/175338v1-max-150x150.png"],     [[250,       70],      "assets/images/resized/0017/5338/175338v1-max-250x250.png"],     [[356,       100],      "assets/images/resized/0017/5338/175338v1-max-450x450.png"]],   "attribution": null}, "products":  [], "relationships":  [{"is_past": false,    "title": "Chairman and CEO",    "person":     {"first_name": "Stephen",      "last_name": "Tullman",      "permalink": "stephen-tullman"}},   {"is_past": false,    "title": "COO \u0026 CFO",    "person":     {"first_name": "Doug",      "last_name": "Gessl",      "permalink": "doug-gessl"}}], "competitions":  [], "providerships":  [], "total_money_raised": "$15M", "funding_rounds":  [{"round_code": "debt_round",    "source_url": "http://ceptaris.com/news/2012FEB21.asp",    "source_description": "CEPTARIS SECURES $15M IN VENTURE DEBT FINANCING",    "raised_amount": 15000000.0,    "raised_currency_code": "USD",    "funded_year": 2012,    "funded_month": 2,    "funded_day": 21,    "investments":     [{"company": null,       "financial_org":        {"name": "Silicon Valley Bank",         "permalink": "silicon-valley-bank-2"},       "person": null},      {"company": null,       "financial_org":        {"name": "Oxford Finance Corporation",         "permalink": "oxford-finance-corporation"},       "person": null}]}], "investments":  [], "acquisition": null, "acquisitions":  [], "offices":  [{"description": "",    "address1": "101 Lindenwood Drive",    "address2": "Suite 400",    "zip_code": "19355 ",    "city": "Malvern",    "state_code": "PA",    "country_code": "USA",    "latitude": null,    "longitude": null}], "milestones":  [], "ipo": null, "video_embeds":  [], "screenshots":  [{"available_sizes":     [[[150,        112],       "assets/images/resized/0017/5337/175337v1-max-150x150.png"],      [[250,        188],       "assets/images/resized/0017/5337/175337v1-max-250x250.png"],      [[450,        338],       "assets/images/resized/0017/5337/175337v1-max-450x450.png"]],    "attribution": null}], "external_links":  []}